K.J. Harrison & Partners Inc bought a new stake in shares of Allergan PLC (NYSE:AGN) during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 2,400 shares of the company’s stock, valued at approximately $554,000.
Several other institutional investors also recently added to or reduced their stakes in the stock. Barnett & Company Inc. acquired a new position in shares of Allergan PLC during the first quarter valued at approximately $111,000. Trust Co. of Vermont increased its position in shares of Allergan PLC by 19.5% in the second quarter. Trust Co. of Vermont now owns 545 shares of the company’s stock valued at $126,000 after buying an additional 89 shares during the period. Ropes Wealth Advisors LLC increased its position in shares of Allergan PLC by 13.2% in the first quarter. Ropes Wealth Advisors LLC now owns 497 shares of the company’s stock valued at $133,000 after buying an additional 58 shares during the period. Integrated Investment Consultants LLC increased its position in shares of Allergan PLC by 35.2% in the second quarter. Integrated Investment Consultants LLC now owns 592 shares of the company’s stock valued at $137,000 after buying an additional 154 shares during the period. Finally, High Point Bank & Trust Co. increased its position in shares of Allergan PLC by 19.9% in the second quarter. High Point Bank & Trust Co. now owns 692 shares of the company’s stock valued at $160,000 after buying an additional 115 shares during the period. 85.19% of the stock is currently owned by hedge funds and other institutional investors.
Allergan PLC (NYSE:AGN) traded down 2.16% during mid-day trading on Monday, reaching $238.68. The company had a trading volume of 2,501,684 shares. Allergan PLC has a 12 month low of $195.50 and a 12 month high of $322.68. The firm’s 50 day moving average price is $244.22 and its 200-day moving average price is $241.68. The company has a market capitalization of $94.51 billion, a price-to-earnings ratio of 22.72 and a beta of 0.73.
Allergan PLC (NYSE:AGN) last released its earnings results on Monday, August 8th. The company reported $3.35 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.34 by $0.01. The firm earned $3.68 billion during the quarter, compared to analyst estimates of $4.10 billion. Allergan PLC had a return on equity of 7.67% and a net margin of 28.06%. Allergan PLC’s revenue was up 1.0% compared to the same quarter last year. During the same period last year, the business posted $4.41 earnings per share. Equities research analysts anticipate that Allergan PLC will post $14.01 earnings per share for the current year.
Several equities analysts have commented on the company. Vetr downgraded Allergan PLC from a “strong-buy” rating to a “buy” rating and set a $283.05 price objective on the stock. in a research report on Monday, August 8th. JPMorgan Chase & Co. set a $325.00 target price on Allergan PLC and gave the stock a “buy” rating in a report on Friday, August 5th. Mizuho upped their target price on Allergan PLC from $232.00 to $246.00 and gave the stock a “neutral” rating in a report on Friday, August 5th. RBC Capital Markets reiterated an “outperform” rating and issued a $300.00 target price (down from $307.00) on shares of Allergan PLC in a report on Wednesday, August 10th. Finally, Credit Suisse Group AG set a $322.00 target price on Allergan PLC and gave the stock a “hold” rating in a report on Wednesday, August 3rd. Seven investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $308.54.
About Allergan PLC
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC (NYSE:AGN).
Receive News & Ratings for Allergan PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC and related companies with MarketBeat.com's FREE daily email newsletter.